Art. 3 Directive (EU) 2004/27

In forcesince 31 Mar 2004cited 9×

Member States shall bring into force the laws, regulations and administrative provisions necessary to comply with this Directive no later than 30 October 2005. They shall immediately inform the Commission thereof.

When Member States adopt these measures, they shall contain a reference to this Directive or shall be accompanied by such a reference on the occasion of their official publication. The methods of making such reference shall be laid down by the Member States.

  • Opinion of Mr Advocate General Mazák delivered on 26 March 2009. The Queen, on the application of Generics (UK) Ltd v Licensing Authority.Decision

    According to Articles 2 and 3 of Directive 2004/27, where the application for authorisation was made before 30 October 2005, the applicable period of protection is that laid down in Article 10 of Directive 2001/83 prior to its amendment by …

    26 Mar 2009 · 62007CC0527

  • BGH, Urteil vom 30. März 2006 - I ZR 24/03Decision

    … Nach Ablauf der Umsetzungsfrist gemäß Art. 3 der Richtlinie 2004/27/EG vom 31. März 2004 am 30. Oktober 2005 ist die Bestimmung des § 2 AMG, die den nationalen Arzneimittelbegriff regelt, richtlinienkonform i.S. des neu gefassten …

    30 Mar 2006 · I_ZR__24-03

  • Judgment of the Court (First Chamber) of 18 June 2009. The Queen, on the application of Generics (UK) Ltd v Licensing Authority.Decision

    According to Articles 2 and 3 of Directive 2004/27, where the application for authorisation was made before 30 October 2005, the applicable period of protection is that laid down in Article 10 of Directive 2001/83 prior to its amendment by …

    18 Jun 2009 · 62007CJ0527

  • Judgment of the Court (First Chamber), 13 March 2014. Octapharma France SAS v Agence nationale de sécurité du médicament et des produits de Decision

    In artikel 3 van die richtlijn, zoals gewijzigd bij richtlijn 2004/27, heet het: „Deze richtlijn is niet van toepassing op: [...] volledig bloed, plasma of bloedcellen van menselijke oorsprong met uitzondering van plasma dat door middel …

    13 Mar 2014 · 62012CJ0512

  • Judgment of the Court (Sixth Chamber) of 27 September 2007. Commission of the European Communities v Czech Republic.Decision

    27 Sep 2007 · 62007CJ0115

  • Opinion of Advocate General Bobek delivered on 7 December 2017. Proceedings brought by Astellas Pharma GmbH.Decision

    The data exclusivity period is currently eight years. [In principle and subject to a transitional regime: reference is often made to the ‘8 + 2 formula’, which comprises eight years of data protection (during which the applicant for a …

    7 Dec 2017 · 62016CC0557

  • Raad van State, 03-06-2009, 200806401/1/H3Decision

    … 2001/83/EG tot vaststelling van een communautair wetboek betreffende geneesmiddelen voor menselijk gebruik. Ingevolge artikel 3 van Richtlijn 2004/27/EG moeten de lidstaten de nodige wettelijke en bestuursrechtelijke bepalingen in werking …

    3 Jun 2009 · ECLI:NL:RVS:2009:BI6074

  • Raad van State, 07-11-2007, 200608238/1Decision

    … en gecontroleerd en waarin het homeopathische karakter door een gedegen bibliografie wordt geschraagd. Ingevolge artikel 3 van Richtlijn 2004/27/EG, voor zover thans van belang, doen de lidstaten de nodige wettelijke en bestuursrechtelijke …

    7 Nov 2007 · ECLI:NL:RVS:2007:BB7305

  • Judgment of the Court (Seventh Chamber) of 27 September 2007. Commission of the European Communities v Ireland.Decision

    Under Article 3 of Directive 2004/27: ‘Member States shall bring into force the laws, regulations and administrative provisions necessary to comply with this Directive no later than 30 October 2005. They shall immediately inform the …

    27 Sep 2007 · 62007CJ0066